US Stock MarketDetailed Quotes
IDYA IDEAYA Biosciences
- 26.780
- +0.240+0.90%
Close Nov 26 16:00 ET
- 27.000
- +0.220+0.82%
Post 19:28 ET
2.31BMarket Cap-11493P/E (TTM)
27.370High26.020Low1.90MVolume26.450Open26.540Pre Close50.94MTurnover2.22%Turnover RatioLossP/E (Static)86.43MShares47.73552wk High1.96P/B2.29BFloat Cap25.20052wk Low--Dividend TTM85.54MShs Float47.735Historical High--Div YieldTTM5.09%Amplitude2.950Historical Low26.787Avg Price1Lot Size
IDEAYA Biosciences Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -63.17%-49.23M | 1.73%-32.88M | -57.36%-43.81M | -32.18%-115.22M | -1.62%-23.75M | -24.86%-30.17M | -67.37%-33.46M | -41.71%-27.84M | -56.29%-87.18M | -40.30%-23.37M |
| Net income from continuing operations | -88.85%-51.82M | -88.97%-52.77M | -67.39%-39.57M | -92.59%-112.96M | -40.30%-33.96M | -1,799.07%-27.44M | -26.61%-27.93M | -68.70%-23.64M | -17.87%-58.66M | -32.88%-24.2M |
| Depreciation and amortization | -1.36%1.01M | 9.92%1.1M | 12.71%1.08M | 14.03%4.01M | 11.06%1.02M | 10.92%1.03M | 16.05%998K | 18.81%960K | 15.93%3.52M | 17.60%922K |
| Change In working capital | 58.56%-2.28M | 280.26%15.7M | 26.75%-5.32M | 69.26%-13.21M | 526.04%8.26M | 81.45%-5.5M | -333.50%-8.71M | 22.69%-7.26M | -124.73%-42.97M | -10.05%-1.94M |
| -Change in receivables | 99.71%-19K | -95.45%14K | 101.17%3K | -78.36%193K | 106.45%6.69M | -106.99%-6.54M | -24.69%308K | -163.30%-257K | 15.25%892K | 3,909.41%3.24M |
| -Change in prepaid assets | -178.69%-934K | 90.44%-371K | -328.19%-3.13M | 3.49%-2.05M | 55.50%-724K | 369.16%1.19M | -760.53%-3.88M | 243.25%1.37M | -1,021.16%-2.12M | -889.81%-1.63M |
| -Change in payables and accrued expense | -160.87%-1.04M | 1,438.23%16.59M | -300.46%-1.73M | -33.65%4.27M | 486.94%4.23M | 144.65%1.72M | -130.91%-1.24M | -142.97%-431K | 19.67%6.44M | 53.52%720K |
| -Change in other current liabilities | 41.05%-280K | -17.21%-538K | -3.10%-465K | -10.18%-1.87M | -10.18%-487K | -10.21%-475K | -10.07%-459K | -10.27%-451K | -10.18%-1.7M | -10.22%-442K |
| -Change in other working capital | ---- | ---- | ---- | 70.41%-13.75M | 62.41%-1.44M | 94.76%-1.38M | 38.21%-3.44M | 30.55%-7.5M | -97.44%-46.48M | -96.21%-3.83M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -63.17%-49.23M | 1.73%-32.88M | -57.36%-43.81M | -32.18%-115.22M | -1.62%-23.75M | -24.86%-30.17M | -67.37%-33.46M | -41.71%-27.84M | -56.29%-87.18M | -40.30%-23.37M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -139.02%-20.04M | 156.48%68.56M | -1,604.91%-353.97M | -374.36%-158.46M | -989.36%-111.94M | 374.83%51.35M | -1,011.54%-121.38M | 232.43%23.52M | 52.05%-33.4M | -2,388.14%-10.28M |
| Net PPE purchase and sale | 24.21%-457K | -10.07%-973K | -2,981.40%-1.33M | 31.22%-2.37M | ---838K | 45.23%-603K | 54.46%-884K | 89.28%-43K | -30.22%-3.44M | --0 |
| Net investment purchase and sale | -137.69%-19.58M | 157.70%69.53M | -1,596.55%-352.65M | -420.97%-156.09M | -981.21%-111.11M | 395.47%51.95M | -889.78%-120.5M | 235.74%23.56M | 55.30%-29.96M | -5,452.08%-10.28M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -139.02%-20.04M | 156.48%68.56M | -1,604.91%-353.97M | -374.36%-158.46M | -989.36%-111.94M | 374.83%51.35M | -1,011.54%-121.38M | 232.43%23.52M | 52.05%-33.4M | -2,388.14%-10.28M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 929.33%286.5M | -79.49%39.18M | 11,831.34%349.11M | 273.30%362.72M | 43,385.80%140.89M | -70.91%27.83M | 38,813.03%191.06M | 348.09%2.93M | -33.20%97.17M | -52.91%324K |
| Net common stock issuance | 957.25%274.66M | -76.39%36.32M | 13,323.83%343.65M | 226.20%309.76M | 24,937.82%127.42M | -72.81%25.98M | 233,139.39%153.81M | 28,544.44%2.56M | -33.71%94.96M | -2,130.43%-513K |
| Net preferred stock issuance | ---- | ---- | ---- | --42.18M | ---- | ---- | ---- | ---- | --0 | ---- |
| Proceeds from stock option exercised by employees | 538.33%11.84M | -92.32%2.86M | 1,392.08%5.46M | 388.97%10.77M | -3,529.63%-28.71M | 1,161.90%1.86M | 6,588.87%37.26M | -44.71%366K | 0.09%2.2M | 17.72%837K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 929.33%286.5M | -79.49%39.18M | 11,831.34%349.11M | 273.30%362.72M | 43,385.80%140.89M | -70.91%27.83M | 38,813.03%191.06M | 348.09%2.93M | -33.20%97.17M | -52.91%324K |
| Net cash flow | ||||||||||
| Beginning cash position | 77.63%183.96M | 62.01%109.1M | 129.53%157.78M | -25.41%68.74M | 49.49%152.57M | 110.45%103.57M | 21.56%67.34M | -25.41%68.74M | 27.74%92.15M | -5.96%102.06M |
| Current changes in cash | 343.27%217.23M | 106.66%74.86M | -3,389.10%-48.67M | 480.27%89.04M | 115.61%5.2M | -7.27%49.01M | 685.64%36.22M | 96.20%-1.4M | -217.02%-23.41M | -103.41%-33.32M |
| End cash Position | 162.95%401.19M | 77.63%183.96M | 62.01%109.1M | 129.53%157.78M | 129.53%157.78M | 49.49%152.57M | 110.45%103.57M | 21.56%67.34M | -25.41%68.74M | -25.41%68.74M |
| Free cash flow | -61.45%-49.69M | 1.42%-33.86M | -61.87%-45.14M | -29.77%-117.59M | -5.20%-24.59M | -21.81%-30.78M | -56.59%-34.34M | -39.09%-27.89M | -55.11%-90.62M | -35.38%-23.37M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data